In 2026, the spotlight will be on a handful of therapeutic strategies that could change cancer care for patients by offering ...

Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...

Jan 22 (Reuters) - Janux Therapeutics said on Thursday it has entered a collaboration with Bristol Myers Squibb to develop a new cancer treatment, sending its shares up more than 12% in premarket ...

A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a ...

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told ...

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid limited options. The FDA has granted orphan drug designation (ODD) to ARB1002, ...

The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare ...

A Roche drug that is one of the company’s top cancer products is expanding to autoimmune disease with a new FDA approval in lupus nephritis. The intravenously infused drug, Gazyva, may now be used to ...

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), the developer of novel, targeted, T cell enhancing therapeutics, and Cancer Research UK, the world’s largest independent ...

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...